Shionogi Acquires Exclusive Marketing and Distribution Rights for CEDAX(R) (ceftibuten) in the United States OSAKA, Japan, and FLORHAM PARK, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Shionogi & Co., Ltd., a leading Japanese pharmaceutical company focused on the development and commercialization of novel therapeutics, has acquired exclusive marketing and distribution rights for CEDAX(R) (ceftibuten) in the United States, including Puerto Rico. Following a brief period of transition, Shionogi USA, Inc., a wholly-owned subsidiary of Shionogi & Co, Ltd., will begin marketing and distributing CEDAX(R). Ownership of the CEDAX(R) NDA will also be transferred to Shionogi USA, Inc. Since it's formation in 2001, Shionogi USA has focused primarily on advancing clinical development programs for novel therapeutics discovered by Shionogi & Co, Ltd.'s research laboratories in Japan. By obtaining exclusive marketing and distribution rights for CEDAX(R), Shionogi USA has now expanded its infrastructure to support commercial activities. In promoting CEDAX(R), Shionogi USA will utilize a contract sales force provided by PDI, Inc. The marketing and distribution of CEDAX(R) in the United States represents a significant milestone in Shionogi's long-term globalization strategy. With the expansion of Shionogi USA, Inc., Shionogi & Co, Ltd. is building the infrastructure and expertise necessary to independently support the development and commercialization of pharmaceutical products in the United States. About Cedax: CEDAX(R), a third generation cephalosporin antibiotic, was originally discovered by Shionogi & Co, Ltd. and licensed to Schering-Plough Corporation outside of Japan. The product received US NDA approval in 1995, and was most recently marketed and distributed in the United States by Biovail Pharmaceuticals Inc. CEDAX(R) is indicated for the treatment of acute exacerbations of chronic bronchitis, acute otitis media, and pharyngitis/tonsillitis. CEDAX(R) is a once a day medication available in capsules and a cherry-flavored suspension. Additional information on CEDAX(R) can be found at http://www.shionogiusa.com/cedax DATASOURCE: Shionogi & Co., Ltd. CONTACT: Shionogi & Co, Ltd., +81-6-6202-2161, or Shionogi USA, Inc., +1-973-966-6900 Web site: http://www.shionogiusa.com/ http://www.shionogi.co.jp/

Copyright